The strategy for treating Alzheimer’s disease involves controlling the level of acetylcholine, a neurotransmitter in cholinergic synapses, by blocking the degradation of acetylcholine using AChE inhibitors. This evidence concerns the gene ACHE and Alzheimer disease.